

US Bill directs VA to adopt 4D lung imaging

16 July 2026

Highlights

- A bipartisan bill has been introduced in the US House of Representatives directing the US Department of Veterans Affairs (VA) to establish a pilot program using 4D functional lung imaging software to identify respiratory disorders and lung disease in Veterans
- The bill defines an eligible product as an FDA-authorised 4D functional lung imaging product that evaluates lung function, a category in which 4DMedical's XV Technology® is a global leader
- The bill continues a sustained line of US congressional and VA interest in 4D functional lung imaging for Veterans dating back to 2022
- The bipartisan bill was jointly introduced by Representatives Juan Ciscomani (Republican, Arizona), and Chris Pappas (Democrat, New Hampshire), both members of the House Committee on Veterans' Affairs
- The bill authorises US\$20 million for the pilot program
- In peer-reviewed multicentre research, 4DMedical's XV Technology® distinguished Veterans with biopsy-confirmed deployment-related constrictive bronchiolitis from healthy controls, even where existing diagnostic tests were normal

Melbourne, Australia, 16 July 2026: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company") a global leader in respiratory imaging technology, today announces the introduction of a bill in the United States House of Representatives (the AIRCARE for Vets act, H.R.9666) that would direct the US Department of Veterans Affairs (VA) to establish a pilot program using advanced 4D functional lung imaging to identify respiratory disorders and lung disease in Veterans.

The bipartisan bill was jointly introduced by Representatives Juan Ciscomani (Republican, Arizona) and Chris Pappas (Democrat, New Hampshire), who are both members of the House Committee on Veterans' Affairs.

Sustained congressional interest in functional lung imaging for Veterans

Congressional interest in functional lung imaging for Veterans is well established. In 2022, the Congressional appropriations committee report for Military Construction and Veterans Affairs referenced emerging technology using existing imaging equipment to derive 4D models of lung function, and urged the Department of Veterans Affairs to evaluate it for population-wide surveillance of Veterans exposed to airborne hazards. That same year, the PACT Act listed constrictive bronchiolitis as a presumptive condition and required the VA to provide toxic-exposure screening to the millions of Veterans in its care. Viewed in this context, the bill reflects a continuing and broadening focus by US lawmakers on 4D functional lung imaging as a tool for Veterans' respiratory health, rather than an isolated proposal.

A significant respiratory health need among Veterans

Veterans experience elevated rates of respiratory disease, much of it associated with exposures sustained during service, and a meaningful proportion goes undetected by standard tests such as spirometry and conventional CT. In peer-reviewed multicentre research, 4DMedical's XV Technology® distinguished Veterans with biopsy-confirmed deployment-related constrictive bronchiolitis from healthy controls, even where standard spirometry was normal. Imaging that can identify these conditions earlier and more



precisely has the potential to materially improve how respiratory illness in veterans is detected and managed.

What the bill provides for

Upon introduction, the bill was referred to the House Committee on Veterans' Affairs, which will consider the legislation and determine whether it should progress through the House legislative process. If enacted, the bill would direct the Secretary of Veterans Affairs to establish a pilot program and to seek an agreement to license an eligible 4D functional lung imaging software product for use at VA facilities. The bill defines an eligible product as a 4D functional lung imaging software product with FDA authorisation to evaluate lung function. 4DMedical's XV LVAS®, an FDA-cleared 4D functional lung imaging product, sits squarely within that definition. The bill authorises appropriations of \$US20m to support the pilot.

Relevance to 4DMedical

4DMedical already has an established commercial footprint in the United States, including a growing base of clinical sites, US reimbursement pathways for its functional and structural imaging products, and a portfolio of FDA-cleared software delivered through a Software-as-a-Service model. The Company is well positioned to support a VA pilot program of the kind contemplated by the bill should it proceed.

Representative Juan Ciscomani (R, Arizona) said:

Our nation's heroes deserve access to quality healthcare, including the most up to date technology to best diagnose service-related conditions. That's what the AIR CARE for Vets Act is all about. Under this bill, veterans suffering from respiratory conditions and lung cancer would receive better quality care at the VA through the use of imaging software equipped to properly evaluate their symptoms. Better imaging software means an improved rate of diagnosis, which would save lives by catching issues like lung cancer sooner. The men and women who have sacrificed so much for our country deserve to know they are receiving the highest level of care possible at all stages, starting with quality evaluation of their symptoms.

Representative Chris Pappas (D, New Hampshire) said:

We owe everything to our veterans, and they deserve access to top of the line health care both during and following their service. Our legislation would establish a pilot program for VA to utilize innovative 4D lung scanning technology, which improves identification of respiratory disorders and lung disease in veterans. For thousands of veterans living in New Hampshire, exposure to burn pits has significantly increased their chances of developing lung disease and this pilot program will improve the resources and care available to them now and in the years to come.

Captain Le Roy Torres (US Army, (Ret) and CoFounder of Burn Pits 360) said:

I wore two uniforms, one for my state and one for my country, and when I came home sick, I was met with doubt and denial. I endured an invasive open lung biopsy searching for answers that revolutionary, 4D functional lung imaging can now provide, identifying respiratory disorders and lung disease with a precision we never had before. These are not minor ailments. They are devastating, progressive, and deadly. This legislation ensures that no Veteran will ever have to fight as long or as hard as we did just to be seen and believed.

4DMedical MD/CEO and Founder Andreas Fouras said:

This \$20m pilot is a landmark step toward improving how respiratory disease is identified, assessed and managed across the U.S. Veterans healthcare system.



I am proud to see bipartisan support in the US congress continue to focus on giving Veterans access to the kind of advanced 4D functional lung imaging that 4DMedical has pioneered. Those who have served carry a disproportionate burden of respiratory disease, and too much of it is missed by the tests in use today. I commend Representatives Ciscomani and Pappas for this leadership, and welcome the focus the House Committee on Veterans' Affairs brings to the health of Veterans.

For many years, 4DMedical has been working to ensure Veterans have access to better answers, earlier diagnosis and more effective pathways to treatment. The entire 4D team stands ready to help the millions of Veterans affected by lung disease, and to support the successful implementation of this pilot and progression onto a larger program.

I look forward to keeping you informed of progress on these efforts, and other exciting progress on our sales pipelines across ANZ, Europe and North America.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio** and 2026 acquisition of **contextflow**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com